Syrios Ioannis

Syrios Ioannis Medical Oncologist

Education & Academic Qualifications

  • Medical License Medical School, University of Athens, Greece 2003
  • Specialty in Medical Oncology 2013
  • Fellowship in Gynecological Cancer 2014
  • PhD Diploma Medical School, University of Athens, Greece 2012
  • MSc on Management of health care units Hellenic Open University 2016
  • ESMO Examination Certificate European Society of Medical Oncology 2012
  • Diploma of the Hellenic Boards of Oncology Hellenic Society of Medical Oncology 2012


Doctoral thesis

  • DNA ploidy and other factors affecting overall survival in patients with advanced gastric adenocarcinoma¨ Medical School, University of Athens, Greece 05.2007- 06.2012

Fellowship in Societies, Membership in Journal Editorial Committees

  • ESMO

  • G.Y.ON (Young Medical Oncologists Working Group)

  • General Medical Council –Specialist registration (από 16/05/2013)

  • Hellenic Society of Medical Oncology (HESMO), Greek Cancer Society

  • Hellenic Cooperative Oncology Group (HeCOG)

  • Hellenic Oncology Research Group (HORG)

  • Fertility Preservation in Cancer Patients (GONEAS)

Editorial Boards

  • Editorial Board Member in “Journal of Balkan Union of Oncology”

  • AD-HOC REVIEWER for peer-reviewed international journals: “Annals of Oncology”, “Br J Surg”, “AJPP”


Work Experience

  • 01.02.2016 – today Medical Oncologist YGEIA & MITERA Hospital

  • 30.01.2014 – 30.01.2016 Consultant Medical Oncologist, 2nd Department of Medical Oncology, “Saint Savvas” Cancer Hospital, Athens, Greece

  • 08.07.2013 – 08.01.2014 Clinical Research Fellow in Gynae/Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom

  • 29.03.2013 – 29.05.2013 Medical Oncologist, 1st Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece

  • 29.03.2009 – 29.03.2013 Resident Doctor in Medical Oncology, 1st Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece

  • 06.2008-12.2008 Resident Doctor in Hematology, Department of Pathophysiology, Medical School, University of Athens, Greece

  • 06.2006-06.2008 Resident Doctor in Internal Medicine, 1st Department of Internal Medicine, Asclepeion General Hospital, Athens, Greece

  • 12.2005-03.2010 Research associate Doctor in Medical Oncology, Department of Pathophysiology, Medical School, University of Athens, Greece

  • 12.2004-08.2005 Compulsory military service as a Sergeant Doctor, Hellenic Army, Air Force

  • 08.2003-08.2004 Rural Doctor at the Health Center of Dimitsana, Arkadia, Greece 

  • 05.2004-08.2004 Rural Doctor at the General Regional Hospital of Tripolis, Greece

Education Experience

  • Tutor in the Hellenic Boards of Oncology 2014

  • Professor of Medical Anatomy and Physiology in Medical Imaging Devices Faculty, Public Institute of Professional Training, Markopoulo, Attiki, Greece 2005–2006


Clinical & Research Interest

Clinical Interest: 

  • Gynecological Oncology & Breast Cancer

  • Urogenital Cancer

  • Gastrointestinal Cancer

  • Lung Cancer

  • High dose chemotherapy with autologous stem cell support in solid tumors

  • Fertility preservation in cancer patients 

Research Interest: 

  • Phase I-II-III Clinical trials in Gynecological Oncology, PARP and immune checkpoint inhibitors in epithelial Ovarian Cancer, Anti-angiogenesis in gynecological tumors. 

  • Leader member in Gynaecological Oncology Research Group in the Hellenic Oncology Research Group (HORG) and Hellenic Cooperative Oncology Group (HeCOG)


Honors & Awards

  • Prize for the best oral presentation “Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study” 7th Congress of Balkan Union of Oncology, Kusadasi, Turkey, 15-19 October 2008

  • Scholarship granted by the Hellenic Society of Medical Oncology (HeSMO), 2013 

  • Scholarship granted by the European School of Oncology (ESO), 2013



  • “Gastric Cancer: From Staging to Surgical Treatment. Procedures, Complications and Oncological Results” NOVA publishers ISBN: 978-1-62081-294-5 Chapter 3: Surgical Treatment of Early and Advanced Disease and Prognostic Factors

  • ¨CRITICAL CARE AND EMERGENCY MEDICINE: MONITORING¨ Pashalidis Editions, Athens 2009 Lung Cancer Monitoring Chapter


Recent Publications

  • Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. Rare Tumors. 2017 Oct 3;9(3):7016

  • An ovarian mature cystic teratoma evolving in squamous cell carcinoma: A case report and review of the literature. Gynecol Oncol Rep. 2016 Dec 18;19:27-30

  • Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non small cell lung cancer patients. Mol Clin Oncol. 2016 Oct;5(4):440-446. 

  • Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2015 Aug;15(8):875-84. 

  • Thymic carcinoma: what after disease progression? J BUON 2014; 19(2): 577-584. 

  • Advances in thymic carcinoma diagnosis and treatment: a review of literature. Med Oncol. 2014 Jul;31(7):44. 

  • Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets – Where Are we Now? Anticancer Res. 2014 May;34(5):2069-77. 

  • Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review. BMC Nephrol. 2013 Apr 12;14(1):84. 

  • DNA ploidy: a prognostic factor of response to chemotherapy and survival in metastatic gastric adenocarcinoma. Anticancer Res. 2013 Mar;33(3):1209-1214

  • Cutaneous metastasis from hepatocellular carcinoma. J BUON. 2012 Oct;17(4):797-798.